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license (http://creative5, 7-dichloro-8-hydroxyquinoline [PBT2, Prana Biotechnology]) for targeting amyloid b (Ab) in
Alzheimer’s disease (AD). In an earlier phase IIa, 3 month trial, PBT2 lowered cerebrospinal fluid
Ab by 13% and improved cognition (executive function) in a dose-related fashion in early AD.
We, therefore, sought to learn whether PBT2 could alter the Ab-PET signal in subjects with prodro-
mal or mild AD, in an exploratory randomized study over a 12-month phase in a double-blind and a
12-month open label extension phase trial design.
Methods: For inclusion, the usual clinical criteria for prodromal or probable AD, Mini–Mental State
Examination 20, and global Pittsburgh compound B (PiB)-PET standardized uptake volume ratio
(SUVR) .1.7 were used. As this was an exploratory study, we included contemporaneous matched
control data from the Australian Imaging Biomarker and Lifestyle Study (AIBL). Other measures
included fluorodeoxyglucose-positron emission tomography, magnetic resonance imaging volumet-
rics, blood Ab biomarkers, and cognition and function.
Results: Forty subjects completed the first 12-month double-blind phase (placebo 5 15,
PBT2 5 25), and 27 subjects completed the 12-month open label extension phase (placebo 5 11,
PBT2 5 16). Overall, PTB2 250 mg/day was safe and well tolerated. The mean PiB-PET SUVR
at baseline was 2.51 6 0.59. After adjusting for baseline SUVR, in the double-blind phase, the pla-
cebo group showed a nonsignificant decline in PiB-PET SUVR, whereas the PBT2 group declined
significantly (P 5 .048). Subjects who did not enter or complete the extension study had a signifi-t declaration: K.J.B. is a paid consultant and R.C. was
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(2.29 6 0.48). Both groups differed significantly from the rate of change over 12 months in the
AIBL control group. In the open label 12-month extension study, the PiB-SUVR stabilized. There
were no significant differences between PBT2 and controls in fluorodeoxyglucose-positron
emission tomography, magnetic resonance imaging volumetrics, blood Ab biomarkers, or cogni-
tion/function over the course of the double-blind phase.
Discussion: There was no significant difference between PBT2 and controls at 12 months, likely due
to the large individual variances over a relatively small number of subjects. PBT2 was associated with
a significant 3% PiB-PET SUVR decline in the double-blind phase and a stabilization of SUVR in the
open-label phase. From this exploratory study, we have learned that the entry criterion of SUVR
should have been set at  1.5 and ,2.0, where we know from the AIBL study that subjects in this
band are accumulating Ab in a linear fashion and that subjects who withdrew from this type of study
have much higher SUVRs, which if not taken into account, could distort the final results. Because of
large individual variations in SUVR, future studies of PBT2 will require larger numbers of subjects
(n . 90 per arm) over a longer period (18 months or more). Further evaluation of higher doses of
PBT2 in earlier stages of AD is warranted.
Trial Registration: ACTRN 12611001008910 and ACTRN 12613000777796.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Randomised control trial; Alzheimer’s disease; Ab-amyloid PET molecular imaging; Novel 8-OH quinoline;Clinical trial design; Biomarkers for Alzheimer’s disease1. Background
The advent of a biomarker definition of sporadic Alz-
heimer’s disease (AD) now allows determination of the effi-
cacy of therapeutic interventions using the two validated
biomarkers of amyloid b (Ab): Ab-PET and cerebrospinal
fluid (CSF)-Ab [1–3]. An abnormally high cortical signal
from Ab-PET reflects the amount of Ab-amyloid closely
associated with an insoluble pool in plaques and
perivascular Ab deposits [4,5], whereas a decreasing CSF-
Ab level may reflect the interstitial diffusible pool of Ab
which feeds irreversibly the more insoluble fibrillary Ab-
amyloid plaque pool [6].
Despite the differing origins of these Ab-biomarker sig-
nals, they are closely interrelated with similar predictive util-
ity for diagnostic classification and progression of cognitive
impairment [7,8]. Longitudinal cohort studies demonstrate
that the Ab burden as measured by PET increases linearly
at about 3% per year in the preclinical and prodromal
stages of AD, which then slows after the full clinical
syndrome of AD has developed [9,10]. Similarly, CSF-Ab
levels decline over time during the evolution of AD [11].
We have been developing a second generation 8-OH
quinoline (2-(dimethylamino) methyl-5, 7-dichloro-
8-hydroxyquinoline [PBT2, Prana Biotechnology]) for
targeting Ab in AD. Originally developed as a metal-
protein attenuating compound [12,13], more recent results
indicate that PBT2 can stabilize a non-toxic oligomeric
(dimeric) conformer of Ab [14]. In a phase IIa, 3-month trial,
(n 5 74) in mild/moderate AD, PBT2 lowered CSF Ab by
13% and improved cognition (executive function) in adose-related fashion [15]. We, therefore, sought to learn
whether changes in the Ab-PET signal could be detected af-
ter PBT2 administration in an exploratory study in a small
number of subjects (n 5 40; 15 placebo and 25 active)
with prodromal or mild AD, over a 12-month phase in a pla-
cebo controlled double-blind study with a 12-month open la-
bel extension phase (the IMAGINE Study; Australian New
Zealand Clinical Trials Registry Trial identifiers ACTRN
12611001008910 and ACTRN 12613000777796).2. Methods
2.1. Study design and participants
The exploratory PBT2-204 IMAGINE study was a 12-
month randomized, double-blind, placebo-controlled phase
with an extension for another 12 months as an open-label
phase. The primary objectives were to assess safety and
tolerability of PBT2, and its effect on Ab amyloid accumu-
lation over these two 1-year intervals in subjects with
prodromal or mild AD. The study was conducted at five sites
in Melbourne from February 2012 through December 2014.
Eligible subjects were 55 years of age, met the criteria
for prodromal or probable AD [16,17], a Mini–Mental State
Examination (MMSE) score  20, a score on the Hachinski
Ischemic scale of four or lower, and a global Pittsburgh
compound B (PiB)-PET standardized uptake volume ratio
(SUVR) . 1.7. Concurrent use of standard anti-
acetylcholinesterase inhibitor AD medications was
permitted.
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disorders associated with dementia; major psychiatric disor-
ders; a history of stroke or clinically significant cardiovascu-
lar disease; an abnormal screening brain magnetic resonance
imaging (MRI) scan (evidence of ischemic necrosis or 2
lacunar lesions); and clinically significant retinal, optic
nerve, or any ocular disease.
In addition to the primary objectives of this exploratory
study (safety, tolerability, and efficacy of 250 mg/d of oral
PBT2, in altering the global PiB SUVR from baseline to
12 months with an open-ended extension to 24 months),
the secondary objectives included assessment of changes
in regional PiB-PET SUVR, glucose metabolism as measured
by fluorodeoxyglucose-positron emission tomography
(FDG-PET), MRI volumetrics (hippocampal, cortical gray
matter, and ventricular volumes), blood-based biomarkers
(APOE [apolipoprotein E] haplotype, Ab plasma levels, and
Ab cellular dimer/monomer levels), and cognition and daily
function.2.2. Study oversight and role of the sponsor and funding
source
The study was approved by the institutional review board
at each participating site. Written informed consent was ob-
tained from the subjects or their legally authorized represen-
tatives or caregivers. The sponsor (Prana Biotechnology)
assisted with the study design, data collection, data analysis,
data interpretation, and writing of the report. All authors had
full access to all the data in the study and were involved in
the development and approval of the manuscript. The first
(V.L.V.) and last (C.L.M.) authors had primary responsibil-
ities for drafting the manuscript and the decision to submit
for publication.Screen x
Aβ-PET x
FDG-PET x
MRI x
Blood x x
Cognion/funconal assessments x x
Neuro- and ophthalmological 
assessments
x x x
-1 0 6
Double blin
3
Fig. 1. Schedule of investigations and assessments. Abbreviations: Ab, amyloid b
netic resonance imaging.2.3. Randomization, masking, and open label extension
For the first 12-month phase, participants were assigned
randomly (2:1) either to PBT2 250 mg once daily or to pla-
cebo. At the conclusion of this phase of the study, the
double-blind results were analyzed and preliminary conclu-
sions were drawn. All site investigators and coordinators
were aware of these preliminary findings, but all participants
and investigators/coordinators remained blinded to which
arm (placebo/active) the participants had been in. All partic-
ipants were then offered the opportunity to participate in a
further 12-month open-label phase. All involved in this
extension phase remained blinded to the treatment assign-
ments in the double-blind phase until after the conclusion
of the extension phase.2.4. Procedures
Subjects underwent a screening visit to access eligibility
followed by a baseline visit within one month, at which they
were allocated to a treatment assignment. The overall
schedule of visits and investigations is set out in Fig. 1.
The primary outcome measure, global PiB SUVR, was
assessed at baseline and 6 and 12 months. Clinical assess-
ment for safety and tolerability included vital signs; routine
clinical laboratory parameters; 12-lead electrocardiogram;
physical, neurological, and ophthalmological examination;
neuropsychiatric inventory; and the Columbia Suicide
Severity Rating Scale.
For the secondary outcome measures, participants under-
went clinical and cognitive assessments at baseline and 6,
12, and 24 months.
Cerebral glucose metabolism was assessed through FDG-
PET at baseline, 12, and 24 months by measuring change inx x x x
x
x x
x x x x
x x
x x x x x x x
12 18 24
(Months)
d phase Open label phase
9 15 21
; FDG-PET, fluorodeoxyglucose-positron emission tomography, MRI, mag-
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24 months.
Brain volumetrics were assessed through MRI scanning
at baseline, 12, and 24 months. The MRI volumetric out-
comes were the changes in hippocampal, cortical gray mat-
ter, and ventricular volumes from baseline to 12 and
24 months.
Blood samples for Ab biomarkers were taken at baseline,
6, and 12 months. Routine clinical biochemistry sampling
occurred at screening, baseline, 6, 12, 18, and 24 months.
Cognition was assessed using a neuropsychological test
battery (NTB) and MMSE. The NTB consisted of the Rey
Auditory Verbal Learning Test Immediate and Delayed
Tests; Wechsler Memory Scale Digit Span Digit Span;
Controlled Oral Word Association Test; Category Naming
Test; Trail Making Test Part A and Part B. Functional
abilities were assessed using the Alzheimer’s Disease
Cooperative Study–Activities of Daily Living inventory
(ADCS-ADL-23).2.5. Image acquisition
2.5.1. PET
PiB-PETacquisitions have been described in detail previ-
ously. Briefly, a 30-min acquisition in 3D mode starting
40 minutes after injection ofw370MBq PiB was performed
with a Phillips Allegro PET camera. A transmission scan
was performed for attenuation correction. PET images were
reconstructed using a 3D RAMLA algorithm.
For the FDG studies, all subjects were fasted for at least
6 hours and were normoglycemic at the time of FDG injec-
tion. A 20-minute static PET emission scan was acquired
30 minutes after injection of w200 MBq 18F-FDG on the
same camera, and images were reconstructed using the
same image reconstruction techniques.
2.5.2. MRI
Participants received an MRI using the Alzheimer’s Dis-
ease Neuroimaging Initiative 3D Magnetization Prepared
Rapid Gradient Echo sequence, with 1! 1 mm in-plane res-
olution and 1.2 mm slice thickness, repetition time/echo
time/relaxation time/VV 5 2300/2.98/900, flip angle 9
and field of view 240 ! 256, and 160 slices. T2 fast spin
echo and fluid-attenuated inversion recovery sequences
were also obtained.2.6. Safety population and monitoring
The safety population included all participants who
received at least one dose of PBT2, had a scan that was pos-
itive for amyloid at baseline (defined as an SUVR.1.7), and
underwent at least one PETassessment after baseline. Safety
was evaluated by means of reports of adverse events (AEs);
clinical laboratory testing (hematologic and serum chemical
testing and urinalysis); assessment of vital signs, physical,
neurological, and ophthalmological examinations; and brainMRI. An independent, external Data and Safety Monitoring
Committee, whose members were aware of the study assign-
ments, reviewed the safety data.2.7. Image analysis
2.7.1. PET
Standardized uptake values (SUVs) for PiB and FDG
were calculated for all brain regions examined. The primary
performance measure used for all the PET assessments was
the SUVR, generated by dividing all regional PiB and FDG
SUV by the respective cerebellar cortex SUV. The global
PIB SUVR was calculated as the average SUVR of the ante-
rior cingulate, posterior cingulate/precuneus, frontal, lateral
temporal, parietal, and occipital cortex. The FDG posterior
cortical index was calculated as the average SUVR of the
lateral temporal, parietal, and posterior cingulate/precuneus
cortices. All measurements were adjusted for baseline
values. Regional SUVR of the individual regions described
above were also examined.
PiB- and FDG-PET images were processed using a semi-
automatic region of interest method as previously described
[18]. Briefly, coregistration of each individual’s MRI with
the PET images was performed with SPM8 [19]. The narrow
cortical region of interest template was placed on the core-
gistered MRI by an operator who was blind to the subject’s
clinical status and then transferred to the coregistered PiB-
and FDG-PET images. Follow-up PET images were
coregistered with the respective initial PiB and FDG images,
and the same region of interest templates were applied.
2.7.2. MRI
Brain volumetrics were derived from T1 Magnetization
Prepared Rapid Gradient EchoMRI images using a commer-
cial software program, NeuroQuant. The primary perfor-
mance measures were the gray cortical matter,
hippocampal and ventricular volumes normalized for head
size using the total intracranial volume.2.8. The AIBL comparator control group
Because of the relatively small number of controls in the
double-blind phase of IMAGINE, we used a larger number
of contemporary, well-matched, observational controls
from the Australian Imaging Biomarker and Lifestyle
(AIBL) longitudinal study, whose imaging and cognitive as-
sessments had been collected using similar methods [20].
We identified 46 AIBL participants with at least two Ab-
PET images at 20-month intervals who were selected on
the same inclusion criterion as IMAGINE and matched
with an almost identical IMAGINE baseline SUVR. Forty
AIBL participants were also matched to the IMAGINE
12-month SUVR.
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2.9.1. Preparation of samples
Venesection was used to collect two 4-mL samples of
whole blood in two ethylenediaminetetraacetic acid vacu-
tainers 1.6 mg/mL (CEDTA, Greiner Bio-One) between the
hours of 9.00 am and 3.00 pm. Blood processing commenced
within 15 minutes of sample acquisition. Both tubes were
centrifuged for 20 minutes at 4C at 1900! g before the up-
per plasma layers were removed and aliquoted. The remain-
ing blood in tube A was titurated to produce a cellular
fraction, which was subsequently aliquoted. For tube B, the
buffy coat layer (found just below the plasma layer) was
removed and added to 250-mL phosphate buffered saline
(PBS). This mixture was titurated and added to 5-mL
Ficoll-Paque PLUS (GE life Sciences) before being spun
for 20 minutes at 20C at 400! g with soft break on. The su-
pernatant was removed and added to 7 mL PBS while the pel-
let was collected and aliquoted as red blood cells. The
supernatant/PBS mix was then centrifuged for 5 minutes at
20C at 1900! g before the resulting supernatant was dis-
carded, and the pellet was resuspended in 500-mL Milli-Q
H2O to give the white blood cell fraction. Multiple aliquots
of each fraction were prepared in low binding polypropylene
tubes, and all samples were stored at 280C until required;
this ensured that all samples only underwent a single
freeze/thaw cycle.
2.9.2. Surface-enhanced laser desorption/ionization time-
of-flight mass spectrometry analysis
Mass spectrometric analysis of the blood fractions were
carried out using ProteinChip PS10 Arrays (Bio-Rad;
CAT #C55-30044) loaded with WO2 (2 mL at 0.25 mg/
mL). Chips were incubated for 2 hours at 20C in a humidity
chamber before excess antibodies were removed, and 10 mL
blocking buffer (0.5 M ethanolamine in PBS) was added and
incubated for 30 min. After the removal of the blocking
buffer, arrays were washed three times for 5 minutes with
120 mL of 0.5 % Triton X-100/PBS (wash-buffer) followed
by three 5-minute washes with 120 mL PBS.
Aliquots of the blood fractions (40 mL) were prepared
with 40 mL of 8 M urea and 480 mL of wash-buffer and
placed for 10 min in an ultrasound bath with ice. One hun-
dred and fifty microliters of sample mix was added to each
spot and incubated at room temperature for 3 hours.
Subsequent to incubation, samples were removed, and the
arrays underwent three 10-second washes on a vigorous
shaking table with 150-mLwash-buffer and 150 mL PBS, fol-
lowed by two washes with 150-mL HEPES. The arrays were
then dried before two 1-mL aliquots of a 50% saturated solu-
tion of SPA EAM were applied, with air-drying between
treatments. The 50% saturated solution was prepared by
suspending 5 mg ProteinChip sinapinic acid - energy
absorbing molecule (Bio-Rad; CAT #C30-00002) in 0.5 %
trifluoroacetic acid (Sigma-Aldrich; St Louis, Missouri),
50% acetonitrile (High performance liquid chromatography[HPLC] grade), 15 % isopropyl alcohol (HPLC grade), and
34.5 % HPLC grade H2O.
Each sample was analyzed in duplicate. All arrays were
analyzed blind to diagnostic status using a ProteinChip
surface-enhanced laser desorption/ionization System Enter-
prise Edition (BioRad). All spectra were internally normal-
ized, and peak intensities were normalized using total ion
current. Peak detection was carried out using the inbuilt Bio-
Rad ProteinChip Data Manager BiomarkerWizard, (Version
3.07.004). Ab species, including potential oxidations, were
matched to peaks within the resulting spectra using M/Z.
2.9.3. Plasma Ab assay and APOE genotyping
Quantification of plasma Ab (fragments 1-40, 1-42, n-40,
and n-42) was achieved using the INNO-BIA plasma Ab
forms assay (Innogenetics NV, Ghent, Belgium) on the Lu-
minex xMAP platform. Preparation of the methods follows
the protocol as described [21]. The 96-well filter plates
(Millipore Corporation, Bedford, Massachusetts) were
drained by vacuum manifold. The mean interassay coeffi-
cients of variation, based on the included low and high kit
standards, were 2.8% and 6.2% for Ab1-40, 7.2% and 4.7%
Ab1-42, 4.4% and 3.8% for Abn-40, and 1.0% and 1.3% for
Abn-42, respectively. The mean intraassay variations for
duplicate samples were 2.7% for Ab1-40, 1.4% for Ab1-42,
3.3% for Abn-40, and 1.9% for Abn-42. APOE genotype
was determined by direct sequencing.2.10. Statistical analysis
The sample size was calculated so that the study would
have 90% power, with the use of a two-sided test and an
alpha level of 0.05, to detect a 20% reduction on global
PiB SUVR between the PBT2 and the placebo group.
Normality of distribution was tested using the Shapiro–
Wilk test and visual inspection of variable histograms. Cat-
egorical differences were evaluated using Fisher’s exact test.
The changes from baseline in global PiB SUVR between
the PBT2 and placebo groups were estimated both by using
paired t-tests with adjustment for baseline SUVR and anal-
ysis of covariance (ANCOVA). In the ANCOVA, SUVR at
the assessment of interest was treated as the dependent var-
iable. Baseline SUVR, the interaction between treatment
and visit, baseline MMSE score, APOE ε4 status, and age
were added to the model as covariates.
For analyses of cognitive change, the prespecified ana-
lyses for the 12-month double-blind placebo-controlled clin-
ical trial defined that the primary performance measure from
each NTB test was compared with the placebo and PBT2
groups at the 12-month assessment using ANCOVA, where
performance at the baseline assessment, age at entry,
APOE ε4 status, andMMSE scorewere treated as covariates.
To examine performance in the open label component, these
same ANCOVAs were re-run to compare differences be-
tween groups at the 24-month assessment, with performance
at the 12-month baseline assessment, age at entry, APOE ε4
Subjects screened
n=75
Subjects enrolled
n=42
Screen failures
n=33
PBT2 250mg
n=27
Placebo
n=15
Completed
n=25
Completed 
n=15
One subject lost to 
follow up
Withdrawn
n=2
Subjects enrolled 
n=12
Subjects enrolled 
n=21
Withdrawn
n=1
Withdrawn
n=5
Completed
n=11
Completed
n=16
Double blind 
phase
Open label 
phase
Fig. 2. Flow diagram for the IMAGINE study (PBT2-204).
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Finally, to explore the extent to which performance in the
NTB changed over the 24-month period, irrespective of
treatment, ANCOVAs were used to compare performance
at the 24-month assessment to that at baseline. In these
models, performance at the baseline assessment age at entry,
APOE ε4 status, and MMSE at entry were treated as covari-
ates.
Data are presented as mean 6 standard deviation unless
otherwise stated. No adjustments for multiple comparisons
were performed.3. Results
The IMAGINE Study ran between February 2012 and
December 2014, with 75 subjects screened, 42 enrolled;
40 subjects completed the first 12-month double-blind phase
(placebo5 15, PBT25 25), and 27 subjects (placebo5 11,
PBT2 5 15) completed the open label extension phase
(Fig. 2). The baseline characteristics and demographics are
summarized in Table 1. In both phases, withdrawals were
considered to be unrelated to drug administration. In the
double-blind phase, two subjects in the PBT2 group with-
drew (one because of acute myeloid leukemia and one
because of a photosensitive rash), and one subject in the pla-
cebo group was lost to follow-up (but was included in thedata analysis). In the extension study phase, 33 accepted
the invitation to participate, 6 withdrew, and 27 subjects
completed the extension study. The 13 subjects who did
not enter or complete the extension study for whatever
reason had a 12-month mean PiB-PET SUVR of
2.68 6 0.55, a value significantly (P 5 .0008) higher than
those who continued in the extension study (SUVR of
2.30 6 0.47).3.1. Safety and tolerability
A total of 199 AEs were reported in the double-blind
phase (118 in the PBT2 group and 81 in the placebo group),
of which 150 were mild, 36 were moderate, and 13 were se-
vere. A summary of AEs is presented in Table 2. Overall,
there was no statistically significant difference in the propor-
tions of AEs in the placebo versus PBT2 groups. Similarly,
there were no significant differences in the routine clinical
chemistry, hematology tests, electrocardiograms, color
vision, visual acuity, and visual fields throughout the
double-blind phase.
AEs in the open label study showed a similar pattern as
seen in the double-blind phase. There were no significant
differences between the placebo-PBT2 group and the
PBT2-PBT2 group. Two serious AEs were reported in
each group in the open-label phase.
Table 1
Baseline characteristics and demographics
Characteristics and
demographics
Double blind Extension AIBL
Placebo (n 5 15) PBT2 (n 5 25) Completers at 12 months (n 5 27) Withdrawals at 12 months (n 5 13) (n 5 46)
Age (years) 72.1 (6.9) 71.4 (10.1) 71.1 (8.2) 74.2 (11.0) 75.0 (7.5)
Gender (M/F) 11/4 11/14 15/12 7/6 28/18
APOE ε41 (%) 10 (67) 19 (76) 21 (78) 8 (62) 37 (80)
Global SUVR
Unadjusted 2.48 (0.41) 2.43 (0.36) 2.26 (0.31)* 2.64 (0.33)y 2.46 (0.30)
Adjusted 2.54 (0.65) 2.48 (0.56) 2.30 (0.47) 2.68 (0.55)z 2.50 (0.49)
FDG-PETx 0.90 (0.09) 0.93 (0.07) 0.89 (0.08) 0.87 (0.07) 2
Hippocampal volumex 3.76 (0.53) 3.88 (0.41) 3.69 (0.48) 3.75 (0.33) 3.57 (0.44)
Gray matter volumex 244.9 (19.0) 246.3 (19.7) 242.4 (24.3) 237.9 (13.3) N/A
Ventricular volumex 29.4 (10.0) 29.0 (12.2) 31.0 (10.8) 34.3 (15.4) 29.7 (11.0)
Blood plasmax Ab40 182.4 (23.5) 192.1 (35.0) 174.7 (32.2) 178.3 (30.6) N/A
Ab42 38.4 (8.4) 40.7 (10.3) 39.5 (10.3) 40.4 (6.4) N/A
Ab monomer 27.6 (12.6) 25.6 (17.3) 14.7 (7.2) 17.0 (8.6) N/A
Ab dimer 135.8 (81.8) 131.5 (110.3) 69.1 (38.3) 90.6 (49.1) N/A
Cognition
MMSE 25.2 (2.2) 23.6 (2.5) 24.4 (2.4) 23.8 (2.8) 24.6 (2.8)
Main composite 0.19 (0.7) 20.07 (0.7) 0.05 (0.8) 20.32 (0.7) N/A
Memory composite 0.40 (1.1) 20.18 (0.9) 20.02 (1.1) 20.34 (0.9) N/A
Executive function composite 0.08 (0.7) 20.02 (0.8) 0.08 (0.7) 20.33 (90.8) N/A
ADCS-ADL-23 64.4 (8.4) 67.4 (8.7) 64.5 (9.4) 62.6 (13.0) N/A
NOTE. Data are mean (standard deviation) or N (%).
Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; APOE, apolipoprotein E; SUVR, standardized uptake volume ratio; FDG-PET,
fluorodeoxyglucose-positron emission tomography; Ab, amyloid b; MMSE, Mini–Mental State Examination; ADCS-ADL, Alzheimer’s Disease Cooperative
Study–Activities of Daily Living; N/A, data not available.
*P , .05.
yP , .001 (compared to completers at 12 months).
zP , .0001 (compared to completers at 12 months).
xAll values adjusted for baseline.
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PBT2 was well tolerated and safe. The safety findings from
this study are consistent with those that would be expected in
a population of elderly adults with prodromal or mild AD.3.2. The effect of APOE haplotype
Because of small numbers and the large proportion of
APOE ε41 subjects in this study, it was not possible to
analyze data for ε41 and ε4- subjects separately.3.3. The effect of PBT2 on Ab-PET
In planning this study, we set the intake criterion of a PiB-
PET SUVR of .1.7. After enrollment, the mean of the
whole group baseline values of 2.51 6 0.59 (n 5 40) was
higher than expected. For comparison with this baseline
SUVR, a matched group of AIBL participants (SUVR
2.53 6 0.47, n 5 46, P 5 .81) was selected.
Reviewing the PiB-PET values for all subjects over both
phases of this study, the variance of scores between and
within individuals was quite large (Fig. 3).We first examined
the effect of baseline SUVR and found a significant differ-
ence between the SUVR change at 12 months between the
placebo group (no effect of baseline SUVR r 5 20.14,
P 5 .63) and the PBT2 group (larger decrease with higherbaseline SUVR, r 5 20.042, P 5 .035) (Fig. 4). Dividing
the groups into those above and below the mean baseline
level (,or .2.5 SUVR), there were no significant differ-
ences seen between the placebo and PBT2 groups on those
,2.5 SUVR, but there was a significant decrease from base-
line only in the PBT2 . 2.5 group (P 5 .0017) (Fig. 5). On
this basis, we concluded that it was appropriate to adjust for
baseline SUVR in subsequent analyses. The changes from
adjusted baseline for the various groups are given in Table 3.
Fig. 6 shows the baseline-adjusted mean SUVR values at
baseline and 12 months of the double-blind phase. There is
no significant difference between the groups with a very
large overlap in standard error of the mean at each time
point. Unexpectedly, the placebo group showed a nonsignif-
icant decline from baseline at 12 months (P5 .06), whereas
the PBT2 group showed a significant decline from their
baseline levels (P 5 .048) (Fig. 6). Comparing the 12-
month differences in slopes in SUVR with the matched
AIBL historical controls (n 5 46), there is a significant dif-
ference in the placebo group (P 5 .013) and PBT2 group
(P 5 .0018).
In the 12-month extension phase, 11 placebo and 16
PBT2 subjects accepted the invitation to participate. Their
SUVR values at baseline, 12, and 24 months are shown in
Fig. 7. At 12 months, the 13 subjects who declined to
participate or who withdrew during the extension phase
Table 2
Summary of adverse events in the double-blind phase
Adverse events
Placebo
group (n 5 15)
PBT2 group
(n 5 27, includes
2 withdrawals)
One of more AE 15 26
Related AE 10 23
Serious AE 4 3
Death 0 1
Nature of AE reported by  2 participants
Cardiac 2 1
Ear 2 0
Eye 5 10
Gastrointestinal 8 7
General 0 5
Immune system 1 3
Infection 11 14
Injury 1 2
Investigational 1 4
Metabolic 3 2
Musculoskeletal 4 6
Neoplasia 0 2
Nervous system 6 17
Respiratory 1 4
Skin 2 8
Abbreviation: AE, adverse event.
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(P5 .0014) higher than the mean SUVR of 2.306 0.47 of
those 27 subjects who completed the full 24-month studyTim
1.60
1.85
2.10
2.35
2.60
2.85
3.10
3.35
-5 5 15 25
SUVR
PLACEBO
Double blind Open label
Fig. 3. Longitudinal PiB data by placebo or active group. Line graphs of indivi
(0–12 months) and open label (12–24 months) phases of the study. Placebo grou
1.7 used as inclusion criteria. Abbreviation: SUVR, standardized uptake volume r(Fig. 6). The mean SUVR of the 11 placebo subjects who
entered the extension study did not decline significantly in
the double-blind phase (P 5 .09), but the mean SUVR of
the 16 PBT2 subjects in the double-blind phase had a
very significant decline from baseline (P 5 .009). Both
groups combined in the extension study showed no signif-
icant change over the 12 months of open label treatment
(P 5 .22). However, the baseline mean SUVR of
2.4 6 0.48 in this combined group was significantly
different from the mean at 24 months (2.336 0.49, paired
t-test, P5 .05) (Fig. 7). The slopes of change in these sub-
jects over 24 months were significantly (P 5 .001)
different from those in the AIBL comparator group
(Fig. 6).
No additional significant effects were observed when the
different regions were separately examined.
3.4. The effect of PBT2 on glucose metabolism
The FDG-SUVR in both placebo and PBT2 groups
declined significantly (P 5 .05, .008 respectively) in the
double-blind phase and then stabilized in those who partici-
pated in the open label study over the ensuing 12 months
(Table 2).3.5. The effect of PBT2 on brain MRI volumetrics
There was a nonsignificant trend for a slower rate of
change in hippocampal atrophy to be slower in the PBT2
group (20.029 cc/yr) compared to the placebo groupe (months)
-5 5 15 25
PBT2
Double blind Open label
dual neocortical PiB SUVR in the different groups, over the double blind
p in blue; PBT2 group in red. Dotted line indicates the SUVR threshold of
atio.
Fig. 4. Relationship between the change (D) in PiB SUVR and baseline PiB SUVR in the different groups, over the double-blind (0–12 months) phase of the
study. While there was a significant correlation between change in PiB SUVR and baseline PiB SUVR in the PBT2 group, this was not observed in the placebo
group. Placebo group in blue; PBT2 group in red. Filled symbol denotes APOE ε4 carriers, while open symbol denotes APOE ε4 noncarriers. Abbreviation:
SUVR, standardized uptake volume ratio.
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not maintained in the subjects who went on to open label,
with continued hippocampal atrophy in both groups
(Table 2). Gray matter volumes decreased significantly on
both groups in the double-blind phase and in the extension
phase (Table 2). Similarly, significant increases in ventricu-
lar volumes were observed over the double-blind and open-
label phases (Table 2).3.6. The effect of PBT2 on blood Ab biomarkers
There was no significant effect of PBT2 on any of the Ab
blood biomarkers at 6 or 12 months in the double-blind
phase of this study.3.7. The effect of PBT2 on cognition and function
For the double-blind part of the clinical trial, no differ-
ence between the placebo and PBT treatment conditions2.0
2.1
2.2
2.3
2.4
2.5
-2 0 2 4 6 8 10 12
SUVR <2.5
Time
n.s.
SUVR
Fig. 5. Longitudinal PiB data by baseline PiB SUVR. Line graphs showing the me
and PBT2 (in red) groups, in those participants with an adjusted baseline PiB SUV
ferences between placebo and PBT2 in either group, there was a significant decre
viation: SUVR, standardized uptake volume ratio; n.s., not significant. ** P , .00was identified for any NTB performance measure. For the
open label part of the trial, performance did not improve
generally at the 24-month assessment relative to the 12-
month assessment. When these data were separated into
those who had and had not been randomized to PBT2 in
the double-blind stage of the trial, no differences between
double-blind treatment groups were observed. Finally,
compared to performance at the baseline assessment, NTB
performance measures at the 24-month assessment had not
changed significantly from baseline. These cognitive results
are summarized in Table 4. Assessment of function (ADCS-
ADL-23) similarly showed no differences between groups
(Table 1).4. Discussion
There is a pressing need for disease modifying therapeu-
tic strategies for AD, and Ab-amyloid remains high on the
list of targets. Recent encouraging results with immuno-2.5
2.6
2.7
2.8
2.9
3.0
-2 0 2 4 6 8 10 12
SUVR >2.5
 (months)
n.s.
**
an (6SEM) PiB SUVR at baseline and at 12 months for the placebo (in blue)
R of either ,2.5 (left) or .2.5 (right). While there were no significant dif-
ase from baseline in the .2.5 PiB SUVR PBT2 group (P 5 .0023). Abbre-
1.
Table 3
Neuroimaging changes from baseline (adjusted) by group
Neuroimaging changes
Double blind Open label
AIBL D/yr
0–12 Mo 12–24 Mo 0–24 Mo
Placebo PBT2 Placebo PBT2 All PBT2
PiB SUVR D/yr (n) 20.08 (15) 20.09* (25) 20.0034 (11) 0.058 (16) 0.033 (27) 20.04 (16) 0.06y (40)
FDG PCI SUVR D/yr (n) 20.034* (15) 20.041* (24) 20.005 (11) 20.002 (14) 20.045z (25) 20.046z (14) N/A
Hippocampal volume D/yr (n) 20.21y (15) 20.11y (25) 20.12* (11) 20.27z (15) 20.33z (26) 20.18z (15) 20.20y (30)
Gray matter volume D/yr 24.15* 25.86y 20.62 27.50y 24.58y 25.92z 27.22y
Ventricular volume D/yr 2.80z 3.15z 3.07z 3.22z 3.16z 2.76z 3.81z
Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; PiB, Pittsburgh compound B; SUVR, standardized uptake volume ratio; FDQ,
fluorodeoxyglucose; PCI, posterior cortical index; N/A, Not available.
*P , .05.
yP , .001.
zP , .0001.
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[23–25] point strongly to intervention at the earliest stages of
AD, as defined by specific imaging and CSF biomarkers.
The failure to date of inhibition or modulation of
g-secretase [26] underscores the hopes held for the
efficacy of b-secretase (BACE1) inhibitors either alone or
in combination [27]. Other approaches which directly or
indirectly target Ab are in varying stages of developmentFig. 6. Longitudinal PiB SUVR data from the IMAGINE double-blind
phase. Line graphs showing the mean (6SEM) PiB SUVR at baseline and
at 12 months for the placebo (blue circles) and PBT2 (red circles) groups.
As a contemporaneous control group, a group of 46 AIBL participants
(black circles) meeting the IMAGINE inclusion criteria and matched for
IMAGINE baseline PiB SUVR. While there were no significant differences
between placebo and PBT2 at 12 months, there was a significant decrease of
0.09 PiB SUVR/yr in the PBT2 group (P5 .048). While the IMAGINE pla-
cebo group showed a nonsignificant decrease of 0.08 PiB SUVR/yr, the
AIBL participants showed a significant increase of 0.04 PiB SUVR/yr
(P5 .0014), and an even greater increase (0.07 PiB SUVR/yr) was observed
in the APOE ε4 placebo group of the bapineuzumab trial [22]. Abbrevia-
tions: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR,
standardized uptake volume ratio. **P , .001.[28–30], including PBT2 representing the class of 8-OH
quinolones [31,32].
PBT2 has completed early phase IIa studies in AD [15]
and Huntington’s disease [33] and, together with this present
exploratory study, has proven to be generally safe and well
tolerated. The lack of cognitive or functional benefits or
any significant effects on glucose metabolism, MRI volu-
metrics, or blood biomarkers is not surprising, given the
small numbers in this exploratory trial. The previous phase
IIa study involving PBT2 [15] had 75 subjects over 3months.
A 13% fall in CSF Ab42 was observed in that study. In the
present study, we focussed attention on the utility of PiB-
PET readouts.
The molecular imaging results in this trial indicate that
PBT2 could lower the PiB-PET Ab signal by 3% over
12 months, in contrast to the 3% increase observed in a
closely matched group taken from the AIBL longitudinal
study. The smaller placebo group showed large variability
and an unexpected nonsignificant decline over the first
12 months, which precluded reaching the primary
outcome measure of the trial (Fig. 3). Future studies will
need to be sufficiently powered to take this variability
into account (see below). The inclusion criterion of
SUVR .1.7 resulted in a group selected with a mean
SUVR of 2.51 6 0.59 which is well within the plateau
phase of fully developed AD [9,10]. Inadvertently, we
may have selected a group of AD subjects who had high
PiB-PET SUVR yet only relatively mild cognitive
impairments (MMSE . 20). In this mild AD range, there
is little or no correlation of cognitive status with
PiB-PET SUVR [34]. A similar phenomenon may also
have occurred in the recently completed trial of solanezu-
mab in mild AD [35]. Interestingly, we observed a signifi-
cant negative correlation of baseline SUVR and change
over 12 months in the PBT2 group but not in the placebo
group (Fig. 4), and that the drug-effect was more evident
2.05
2.10
2.15
2.20
2.25
2.30
2.35
2.40
2.45
2.50
2.55
2.60
2.65
2.70
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AIBL 
** 
* 
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SUVR
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Fig. 7. Longitudinal PiB SUVR data from participants who completed the two phases of the IMAGINE study. Line graphs showing the mean (6SEM) PiB
SUVR at baseline and at 12 months for 11 placebo (blue circles) and 16 PBT2 (red circles) participants in the IMAGINE double-blind phase of the study.
In purple triangles, the 27 participants who completed the open label extension study. As comparison group, a group of 40 AIBL participants (black squares)
meeting the IMAGINE inclusion criteria and matched for the baseline PiB SUVR of the 27 participants who completed the two phases of the IMAGINE study.
While therewere no significant differences between the 11 placebo and 16 PBT2 participants at 12months, therewas a significant decrease of 0.14 PiB SUVR/yr
in the PBT2 group (P 5 .005). While the 11 IMAGINE placebo participants showed a nonsignificant decrease of 0.07 PiB SUVR/yr, the AIBL participants
showed a significant increase of 0.04 PiB SUVR/yr (P 5 .0014). While no significant changes in PiB SUVR from 12 to 24 months were observed on the 27
participants who completed the IMAGINE open-label phase, a significant decrease of 0.04 PiB SUVR/yr (P 5 .05) was observed when changes in PiB
SUVR from 0 to 24 months were considered. Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standardized uptake volume
ratio. *P , .05; **P , .001.
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larger studies would be required to confirm this effect.
However, conducting this type of study at the higher
(nonlinear) end of the SUVR spectrum may be counter-
productive.
We noted that the subjects who did not enter or who drop-
ped out of the extension phase had significantly higher
SUVRs than those who completed. This probably reflectsTable 4
Cognitive scores: adjusted group means (1SE) for the placebo and PBT groups f
Cognitive scores
Double blind Open lab
0–12 Mo D/yr 12–24 M
Placebo N 5 12 PBT2 N 5 21 Placebo
Category fluency 10.95 (0.86) 9.74 (0.63) 7.77 (
Verbal fluency 25.37 (2.60) 30.46 (1.89) 28.38 (
RAVLT acquisition 34.98 (3.13) 37.1 (2.27) 27.86 (
RAVLT delay 2.44 (0.82) 2.65 (0.57) 1.98 (
Trial making B 160.24 (12.69) 167.36 (9.48) 106.73 (
Digit span 13.38 (0.98) 14.79 (0.71) 13.71 (
Abbreviation: RAVLT, Rey Auditory Verbal Learning Test.on the poorer physical well-being of those subjects who are
carrying higher Ab burdens and should be a warning for clin-
ical trialists to take these drop-outs into consideration when
interpreting trial results. In the 27 subjects who did complete
both phases of this study, the PBT2 group showed a highly
significant fall in the first 12 months (Fig. 7), coming off a
baseline value of 2.42 6 0.51. This would suggest that even
lower starting baselines should have been employed.or the double blind and open-label phases of the IMAGINE trial
el
o D/yr 0–24 Mo D/yr
N 5 11 PBT2 N 5 16 All N 5 27 PBT2 N 5 27
1.16) 10.9 (0.94) 9.34 (0.70) 9.38 (0.69)
2.28) 27.43 (1.84) 27.90 (1.35) 27.23 (1.78)
2.29) 35.04 (2.29) 31.45 (1.70) 30.99 (2.30)
0.46) 1.77 (0.37) 1.87 (0.28) 1.83 (0.49)
21.01) 99.48 (17.14) 103.10 (12.10) 102.27 (12.59)
0.82) 13.45 (0.65) 13.58 (0.48) 13.49 (0.57)
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Fig. 8. Comparison of the IMAGINE study PiB results with the reported PiB results of the bapineuzumab trial [22,36], and the florbetapir results from the
aducanumab trial [25]. To allow comparison between the different Ab tracers, florbetapir SUVRWCb are expressed in PiBCb-like units called BeCKeTs
[37]. A striking difference between the IMAGINE and the bapineuzumab and aducanumab trials is the Ab burden at baseline. Overall, IMAGINE par-
ticipants not only had significantly higher baseline Ab burden, these baseline values were at levels for which we have demonstrated the rates of Ab accu-
mulation slow [9], making it difficult to discriminate between a potential drug effect that slows Ab accumulation and the natural slowing that occurs at
those SUVR levels. These comparisons highlight the importance of not only establishing a SUVR floor, but also the need of establishing a SUVR ceiling to
ensure all participants are accumulating Ab at a similar rate. Abbreviations: AIBL, Australian Imaging Biomarker and Lifestyle Study; SUVR, standard-
ized uptake volume ratio. * P , .05; ** P , .001.
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have used PiB-PET as a biomarker, we note that the
bapineuzumab APOE ε4 carrier subgroup had a mean
baseline SUVR of 2.11 6 0.33 and showed a drug effect
of 4.8% over 18 months [22,36] (Fig. 8). The recently re-
ported aducanumab phase 1 study had intake criteria of
PiB-equivalent of w1.9-2.1 [25] (see also Fig. 8), and
the AZD 3293 trial of a BACE 1 inhibitor has intake
criteria of PiB-equivalent w1.6-2.0 [38]. Based on
Ab-CSF levels, we infer that the intake PiB SUVR of
the PBT2 Euro study was w2.15 [39]. Taken together,
these observations suggest that the IMAGINE PiB base-
line was exceptionally high, and that future studies should
aim for intake PiB SUVR between 1.5 and 2.0, a value
which is well-within the linear rates of change as seen
in AIBL and other longitudinal studies [9,10]. This will
necessitate a trade-off between milder levels of cognitive
impairment on the preclinical/prodromal stages of AD
(with consequent loss of power in detecting cognitive
change) and improving the signal: noise rations in the
linear-change region of the SUVR. If the SUVR results
of the present study are to be confirmed, we calculate
that a minimum of 90 subjects per arm will be required,
over a longer period (18 months). Finally, having a lowernumber of subjects randomized to placebo than to the
active treatment might reduce the chances to see a drug ef-
fect, due to a larger variance in the placebo group as
observed in this study. A more balanced approach should
be taken [40].
Future progress in achieving disease modification in AD
is dependent on the three strategic arms of determining
maximal tolerated dose, exploring rational combinations of
therapeutics, and design of “super-adaptive” trials with
frequent interim biomarker analyses [41]. Data from this
exploratory IMAGINE study and the further clinical devel-
opment of PBT2 could be useful in developing each of these
strategic arms.Acknowledgment
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1. Systematic review: We reviewed all publications
and disclosures of clinical trials employing amyloid
b-PET molecular imaging as a biomarker readout
for Ab amyloid–targeted modifying therapeutic
strategies in Alzheimer’s disease (AD).
2. Interpretation: This exploratory trial did not show ef-
ficacy of PBT2 in a small double-blinded study.
However, subjects recruited had a mean baseline
PiB-PET standardized uptake volume ratio of 2.51,
much higher than anticipated, and this may have
contributed to the failure.
3. Future directions: Setting an upper level on the PET-
standardized uptake volume ratio at the time of
recruitment might help ensure that subjects fall into
the linear accumulation phase of AD. Further eval-
uation of PBT2 in earlier stages of AD is warranted.References
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